November 25, 2024 11:36 AM ESTUpdated 11:53 AM

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Incyte’s monoclonal antibody Monjuvi reduced certain follicular lymphoma patients’ risk of progression, relapse or death by 57% compared to placebo, the company announced Monday. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Editor

Senior Editor

Sign up to read this article for free.

more like this

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA